GlassScriptPhysician profile
Millicent M Edgar
NPI 1437452760
$4,803.38
in general payments reported to CMS, 2019-2025
27 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,049 · 2023: $1,051 · 2024: $1,292 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,754.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $426.01 | 2025 | Krystexxa |
| Janssen Scientific Affairs, LLC | $404.43 | 2023-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $364.62 | 2023-2024 | Soliris, Strensiq |
| Abbvie INC. | $351.57 | 2022-2023 | |
| Hologic Sales and Service, LLC | $319.37 | 2025 | Aptima |
| Coloplast Corp | $278.05 | 2023-2024 | Titan |
| Boston Scientific Corporation | $256.17 | 2022 | |
| Genzyme Corporation | $240.09 | 2022-2024 | |
| Novo Nordisk INC | $193.38 | 2022-2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $190.79 | 2023 | Quviviq |
| Myriad Genetic Laboratories, INC. | $182.79 | 2022 | |
| Sanofi Pasteur INC. | $182.47 | 2022-2023 | |
| Vertex Pharmaceuticals Incorporated | $168.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $120.53 | 2024 | Airsupra |
| Sumitomo Pharma America, INC. | $118.22 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $117.21 | 2023 | Mild Device Kit |
| Neurocrine Biosciences, INC. | $116.68 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $102.32 | 2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $100.68 | 2025 | Symbravo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $94.28 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.75 | 2025 | |
| Jazz Pharmaceuticals INC. | $82.56 | 2022 | |
| Cequr Corporation | $80.77 | 2024 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $77.19 | 2024 | |
| Emd Serono, INC. | $75.79 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $43.40 | 2024 | Rexulti |
| Biogen, INC. | $24.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millicent Edgar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.